The Neuroscience New Product Commercialization supports the successful commercialization of products through strategic planning as well as, implementation of pre-launch non-promotional activities. Also, I will be overseeing US commercial interests for phase 2 and phase 3 products in various diseases such as major depressive disorder, Fragile X Syndrome, and Down’s Syndrome. In addition, I will be providing analyses to commercial leadership for business development projects within several disease areas.